S3-E34.4 – ILC 2022 Looking Back: Crystal Balling & The Semaglutide Trial
The group discusses implications of the semaglutide cirrhosis late-breaker and shares what they anticipate might be different one year from now.
July 3, 2022
The group discusses implications of the semaglutide cirrhosis late-breaker and shares what they anticipate might be different one year from now.
Stephen Harrison leads the regular Surfers, Mazen Noureddin and Michelle Long through a discussion of Phase 1 results for pemvidutide, Altimune’s dual GLP-1/glucagon agonist for obesity (and presumably NASH), based on his presentation at ILC2022.
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among
